Citations

Clear

167 citation(s) found for "Grogan, M".

Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay
Muchtar, Eli , Kumar, Shaji , Grogan, Martha , AbouEzzeddine, Omar F. , Jaffe, Allan S. , Muchtar, E , Gertz, Morie A. , Jaffe, Allan S. , Dispenzieri, Angela , AbouEzzeddine, Omar F

Mayo Clinic

Blood | December 13, 2018 | Volume: 133 | Issue: 7 | Pages: 763-766

10.1182/blood-2018-10-875252 | PMID 30545829 Get It

Dosimetry for the study of medical radiation workers with a focus on the mean absorbed dose to the lung, brain and other organs
Yoder, R. Craig , Dauer, Lawrence T. , Balter, Stephen , Grogan, Helen A. , Passmore, Christopher, Rothenberg, L. N., Vetter, Richard J., Boice, John D. , Mumma, Michael T.

Mayo Clinic

International Journal of Radiation Biology | November 20, 2018 | Volume: 98 | Issue: 4 | Pages: 619-630

10.1080/09553002.2018.1549756 | PMID 30451566 Get It

P2925Outcomes of direct current cardioversion in adults with cardiac amyloidosis
El‐Am, Edward , Grogan, Martha , Ammash, Naser M., Melduni, Rowlens M. , Hodge, David O. , Lin, Grace , Dispenzieri, Angela , White, Richard D. , Noseworthy, Peter A. , Pislaru, Sorin V. , Nkomo, Vuyisile T.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy565.p2925 Get It

Multicenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer
Sanoff, Hanna K. , Goldberg, Richard M. , O’Reilly, Séamus , Kasbari, Samer S. , McDermott, Ray , Moore, Dominic T., Zamboni, William C. , Grogan, William, Cohn, Allen Lee, Bekaii‐Saab, Tanios , Leonard, Gregory , Ryan, Theresa, Olowokure, Olugbenga, Fernando, Nishan H., McCaffrey, John , El‐Rayes, Bassel F. , Horgan, Anne M., Sherrill, Gary B., Yacoub, George Hosni, O’Neil, Bert H. , El-Rayes, Bassel F , Bekaii-Saab, Tanios S , McDermott, Ray , Ivanova, Anastasia , Kim, Richard D. , Sanoff, Hanna

Mayo Clinic

Cancer | June 15, 2018 | Volume: 124 | Issue: 15 | Pages: 3118-3126

10.1002/cncr.31552 | PMID 29905927 Get It

BACKGROUND Regorafenib, a multikinase inhibitor that inhibits angiogenesis, growth, and proliferation, prolongs survival as monotherapy in patients with refractory colorectal cancer. This international, double‐blind, placebo‐controlled, multicenter trial assessed the efficacy of regorafenib with folinic acid, fluorouracil, and irinotecan (FOLFIRI) as a second‐line treatment for metastatic colorectal cancer. METHODS Patients with metastatic colorectal cancer who progressed on first‐line oxaliplatin and fluoropyrimidine enrolled at 45 sites in the United States and Ireland. Patients, stratified by prior bevacizumab use, were randomized 2:1 to regorafenib or placebo. The treatment consisted of FOLFIRI on days 1 and 2 and days 15 and 16 with 160 mg of regorafenib or placebo on days 4 to 10 and days 18 to 24 of every 28‐day cycle. Crossover was not allowed. The primary endpoint was progression‐free survival (PFS). Under the assumption of a 75% event rate, 180 patients were required for 135 events to achieve 90% power to detect a hazard ratio (HR) of 0.65 with a 1‐sided α value of .1. RESULTS One hundred eighty‐one patients were randomized (120 to regorafenib‐FOLFIRI and 61 to placebo‐FOLFIRI) with a median age of 62 years. Among these, 117 (65%) received prior bevacizumab or aflibercept. PFS was longer with regorafenib‐FOLFIRI than placebo‐FOLFIRI (median, 6.1 vs 5.3 months; HR, 0.73; 95% confidence interval [CI], 0.53‐1.01; log‐rank P = .056). The median overall survival was not longer (HR, 1.01; 95% CI, 0.71‐1.44). The response rate was higher with regorafenib‐FOLFIRI (34%; 95% CI, 25%‐44%) than placebo‐FOLFIRI (21%; 95% CI, 11%‐33%; P = .07). Grade 3/4 adverse events with a >5% absolute increase from regorafenib included diarrhea, neutropenia, febrile neutropenia, hypophosphatemia, and hypertension. CONCLUSIONS The addition of regorafenib to FOLFIRI as second‐line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018. © 2018 American Cancer Society .
Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis
Milani, Paolo , Perlini, Stefano , Mussinelli, Roberta , Lacy, Martha Q. , Kumar, Shaji , Merlini, Giampaolo , Hayman, Suzanne R. , Dingli, David , Klarich, Kyle W. , Lust, John A., Lin, Yi , Kapoor, Prashant , Pellikka, Patricia A. , Hwa, Yi L. , Zeldenrust, Stephen R., Kyle, Robert A. , Grogan, Martha , Merlini, Giampaolo , Milani, Paolo , Pellikka, Patricia A , Dingli, David , Lin, Yi , Dispenzieri, Angela , Scott, Christopher G. , Gertz, Morie A. , Buadi, Francis K. , Maurer, Matthew J. , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent , Mussinelli, Roberta , Perlini, Stefano

Mayo Clinic

Circulation: Cardiovascular Imaging | May 11, 2018 | Volume: 11 | Issue: 5 | Pages: No page available

10.1161/circimaging.117.006588 | PMID 29752392 Get It

Background: Heart involvement is the most important prognostic determinant in AL amyloidosis patients. Echocardiography is a cornerstone for the diagnosis and provides important prognostic information. Methods and Results: We studied 754 patients with AL amyloidosis who underwent echocardiographic assessment at the Mayo Clinic, including a Doppler-derived measurement of stroke volume (SV) within 30 days of their diagnosis to explore the prognostic role of echocardiographic variables in the context of a well-established soluble cardiac biomarker staging system. Reproducibility of SV, myocardial contraction fraction, and left ventricular strain was assessed in a separate, yet comparable, study cohort of 150 patients from the Pavia Amyloidosis Center. The echocardiographic measures most predictive for overall survival were SV index <33 mL/min, myocardial contraction fraction <34%, and cardiac index <2.4 L/min/m 2 with respective hazard ratios (95% confidence intervals) of 2.95 (2.37–3.66), 2.36 (1.96–2.85), and 2.32 (1.91–2.80). For the subset that had left ventricular strain performed, the prognostic cut point was −14% (hazard ratios, 2.70; 95% confidence intervals, 1.84–3.96). Each parameter was independent of systolic blood pressure, Mayo staging system (NT-proBNP [N-terminal pro-B-type natriuretic peptide] and troponin), and ejection fraction on multivariable analysis. Simple predictive models for survival, including biomarker staging along with SV index or left ventricular strain, were generated. Conclusions: SV index prognostic performance was similar to left ventricular strain in predicting survival in AL amyloidosis, independently of biomarker staging. Because SV index is routinely calculated and widely available, it could serve as the preferred echocardiographic measure to predict outcomes in AL amyloidosis patients.
MRI feature tracking strain is prognostic for all-cause mortality in AL amyloidosis
Illman, Jeffery E., Arani, Arvin , Chang, Ian C , Glockner, James F., Grogan, Martha , Araoz, Philip A. , Arunachalam, S P , Arani, Arvin , Chang, Ian Cheng-Yi , Dispenzieri, Angela , Grogan, Martha , Araoz, Philip A , Arunachalam, Shivaram P. , Dispenzieri, Angela

Mayo Clinic

Amyloid | May 7, 2018 | Volume: 25 | Issue: 2 | Pages: 101-108

10.1080/13506129.2018.1465406 | PMID 29733684 Get It

Outcomes After Cardiac Transplant for Wild Type Transthyretin Amyloidosis
Rosenbaum, Andrew , AbouEzzeddine, Omar F. , Grogan, Martha , Kushwaha, Sudhir S. , Clavell, Alfredo L. , Daly, Richard C. , Edwards, Brooks S., Rosenbaum, Andrew N , Kushwaha, Sudhir, Clavell, Alfredo, Dispenzieri, Angela , AbouEzzeddine, Omar F

Mayo Clinic

Transplantation | April 20, 2018 | Volume: 102 | Issue: 11 | Pages: 1909-1913

10.1097/tp.0000000000002240 | PMID 29677073 Get It

Background The true prevalence of heart failure due to wild type transthyretin amyloidosis (ATTRwt) is likely underestimated. There is a paucity of data with regard to the management of ATTRwt-related advanced heart failure and the natural history of extracardiac ATTRwt. Methods We conducted a retrospective cohort study of patients undergoing cardiac transplant (HTx) for ATTRwt at a single institution. Comprehensive clinical data, including baseline hemodynamic and echocardiographic characteristics, and posttransplant outcomes, were obtained. Results Seven patients with ATTRwt underwent HTx between 2007 and 2015. All patients were male with a mean age of 66 ± 9. Patients had a reduced ejection fraction (mean, 37 ± 14%) and elevated filling pressures pre-HTx (mean pulmonary capillary wedge pressure 22 ± 7 mm Hg) before HTx. Three-year survival was 100%; 1 patient died of pancreatic cancer 45 months post-HTx (1 death per 30.8 patient-years). Oxygen consumption (Δ +6.8 ± 4.9 mL·kg−1·min−1) and 6-minute walk distances (Δ +189 ± 60 m) improved. Symptomatic gastrointestinal involvement (n = 2) and peripheral nerve involvement (n = 4) by ATTRwt developed late. Conclusions This is the first report of a series of ATTRwt patients receiving HTx in which excellent outcomes are demonstrated. Although cardiac death is averted, systemic manifestations of ATTRwt may develop posttransplantation.
Hydroxychloroquine-Mediated Cardiotoxicity With a False-Positive 99m Technetium–Labeled Pyrophosphate Scan for Transthyretin-Related Cardiac Amyloidosis
Chang, Ian C , Bois, John P. , Bois, Melanie C. , Maleszewski, Joseph J. , Johnson, Geoffrey B. , Grogan, Martha , Chang, Ian C Y, Johnson, Geoffrey B

Mayo Clinic

Circulation: Cardiovascular Imaging | December 30, 2017 | Volume: 11 | Issue: 1 | Pages: No page available

10.1161/circimaging.117.007059 | PMID 29288196 Get It

Assessment of Fluorodeoxyglucose F18–Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules
Deppen, Stephen A. , Mercaldo, Sarah , Blume, Jeffrey D. , Montgomery, Chandler , Vaszar, Laszlo T. , Isbell, James M. , Rickman, Otis B. , Pinkerman, Rhonda, Lambright, Eric S., Nesbitt, Jonathan C., Grogan, Eric L. , Maiga, Amelia Walling , Williamson, Christina

Mayo Clinic

JAMA Surgery | November 8, 2017 | Volume: 153 | Issue: 4 | Pages: 329

10.1001/jamasurg.2017.4495 | PMID 29117314 Get It